These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 36407022)

  • 1. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy and the impact of mavacamten.
    Mathai S; Williams L
    Ther Adv Chronic Dis; 2022; 13():20406223221136074. PubMed ID: 36407022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy.
    Ho CY; Olivotto I; Jacoby D; Lester SJ; Roe M; Wang A; Waldman CB; Zhang D; Sehnert AJ; Heitner SB
    Circ Heart Fail; 2020 Jun; 13(6):e006853. PubMed ID: 32498620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy.
    Reyes KRL; Bilgili G; Rader F
    Heart Int; 2022; 16(2):91-98. PubMed ID: 36741099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contemporary Therapies and Future Directions in the Management of Hypertrophic Cardiomyopathy.
    Packard E; de Feria A; Peshin S; Reza N; Owens AT
    Cardiol Ther; 2022 Dec; 11(4):491-507. PubMed ID: 36243823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy.
    Zampieri M; Argirò A; Marchi A; Berteotti M; Targetti M; Fornaro A; Tomberli A; Stefàno P; Marchionni N; Olivotto I
    Curr Cardiol Rep; 2021 Jun; 23(7):79. PubMed ID: 34081217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D;
    Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mavacamten, a novel revolutionizing therapy in hypertrophic obstructive cardiomyopathy: A literature review.
    Aguiar T; Martins E
    Rev Port Cardiol; 2022 Aug; 41(8):693-703. PubMed ID: 36073269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Genetic Basis of Hypertrophic Cardiomyopathy.
    Marian AJ
    Circ Res; 2021 May; 128(10):1533-1553. PubMed ID: 33983830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study.
    Cremer PC; Geske JB; Owens A; Jaber WA; Harb SC; Saberi S; Wang A; Sherrid M; Naidu SS; Schaff H; Smedira NG; Wang Q; Wolski K; Lampl KL; Sehnert AJ; Nissen SE; Desai MY
    Circ Cardiovasc Imaging; 2022 Dec; 15(12):e014986. PubMed ID: 36335645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mavacamten - a new disease-specific option for pharmacological treatment of symptomatic patients with hypertrophic cardiomyopathy.
    Pysz P; Rajtar-Salwa R; Smolka G; Olivotto I; Wojakowski W; Petkow-Dimitrow P
    Kardiol Pol; 2021; 79(9):949-954. PubMed ID: 34268723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions.
    Dong T; Alencherry B; Ospina S; Desai MY
    Drug Des Devel Ther; 2023; 17():1097-1106. PubMed ID: 37064432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.
    Desai MY; Wolski K; Owens A; Naidu SS; Geske JB; Smedira NG; Schaff H; Lampl K; McErlean E; Sewell C; Zhang D; Edelberg JM; Sehnert AJ; Nissen SE
    Am Heart J; 2021 Sep; 239():80-89. PubMed ID: 34038706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small Molecules acting on Myofilaments as Treatments for Heart and Skeletal Muscle Diseases.
    Alsulami K; Marston S
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33339418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-modality management of hypertrophic cardiomyopathy.
    Rao SJ; Iqbal SB; Kanwal AS; Aronow WS; Naidu SS
    Hosp Pract (1995); 2023 Feb; 51(1):2-11. PubMed ID: 36598161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging Medical Treatment for Hypertrophic Cardiomyopathy.
    Argirò A; Zampieri M; Berteotti M; Marchi A; Tassetti L; Zocchi C; Iannone L; Bacchi B; Cappelli F; Stefàno P; Marchionni N; Olivotto I
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33804412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mavacamten-A Targeted Therapy for Hypertrophic Cardiomyopathy.
    Schenk A; Fields N
    J Cardiovasc Pharmacol; 2023 May; 81(5):317-326. PubMed ID: 36878205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults.
    Dong T; Nissen S; Ospina S; Desai MY
    Expert Rev Cardiovasc Ther; 2023 Jan; 21(1):5-13. PubMed ID: 36522857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Era: Mavacamten for Obstructive Hypertrophic Cardiomyopathy.
    Woodland M; Al-Horani RA
    Cardiovasc Hematol Agents Med Chem; 2023; 21(2):78-83. PubMed ID: 36278454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.
    Marian AJ; Braunwald E
    Circ Res; 2017 Sep; 121(7):749-770. PubMed ID: 28912181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies.
    Kawana M; Spudich JA; Ruppel KM
    Front Physiol; 2022; 13():975076. PubMed ID: 36225299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.